LY-341,495

LY-341,495

0LY-341,495 is a pharmacological compound that acts as a potent and selective antagonist for the metabotropic glutamate receptors (mGluRs), specifically the mGluR2 and mGluR3 subtypes. It was first synthesized and studied by the pharmaceutical company Eli Lilly.

Chemistry

LY-341,495 is a synthetic compound that belongs to the class of phenylglycine derivatives. Its chemical structure is characterized by a phenyl ring attached to a glycine moiety, which is responsible for its activity at the mGluR2 and mGluR3 receptors.

Pharmacology

LY-341,495 acts as a non-competitive antagonist at the mGluR2 and mGluR3 receptors. These receptors are part of the larger family of metabotropic glutamate receptors, which are G protein-coupled receptors that respond to the neurotransmitter glutamate. By blocking the activity of these receptors, LY-341,495 can modulate glutamatergic neurotransmission in the brain.

Clinical significance

Research into the effects of LY-341,495 has suggested potential applications in the treatment of various neurological and psychiatric disorders. For example, it has been studied in preclinical models of schizophrenia, anxiety disorders, and major depressive disorder. However, further research is needed to fully understand the therapeutic potential of this compound.

See also

• Metabotropic glutamate receptor
• Eli Lilly and Company
• Phenylglycine